MHC class I and MHC class II molecules have long been intensively studied, and this has resulted in a global view of these processes. New technologies, including genome-wide small interfering RNA ...

MHC class I molecules are ligands for the killer-cell immunoglobulin-like receptors (KIRs), which are expressed by natural killer cells and T cells. The interactions between these molecules ...

Major histocompatibility complex (MHC) molecules have been categorized as either class I or class II. Now, researchers from Fujita Health University, Japan, discovered a third ancient category.

MHC class I antigens present epitopes derived mainly from intracellular proteins to the immune system, and suppression of these molecules leads to insufficient antigen presentation, ...

Genotyping of HLA class I loci was performed for 850 patients who seroconverted and had known dates of HIV-1 infection. Survival analyses with respect to the rate of progression to AIDS were ...

The vaccine derived-peptide binds MHC class I molecules (5). Peptide antigen/MHC I complexes are presented on the cell surface (6), binding cytotoxic CD 8+ lymphocytes, and inducing a cell ...

21 Nov 2007. Adapted from a story that originally appeared on the Schizophrenia Research Forum.. It may be a surprising idea, but it is becoming clearer from work done in several labs that complement ...

Compass Therapeutics. Major Histocompatibility Complex Class I (MHC-I) negative tumors are refractory to immune-oncology therapies, including resistance to checkpoint blockers, due to the loss of ...

Background: The immune system is alerted for virally infected cells in the body by the antigen presentation pathway, which is in turn mediated by the major histocompatibility complex (MHC) class I and ...

Although we can provide MHC class I tetramers with either human or murine b2-microglobulin, we typically fold all tetramers of every species with human b2-microglobulin. Use of murine b2-microglobulin ...

Breakthrough nanovaccine uses tumor cell membranes and immune-boosting polymers to enhance personalized cancer immunotherapy, showing strong results in preclinical models.